| abstract |
Modified natriuretic compounds and complexes thereof are disclosed in the complexes. Specifically, a composite form of BNP is provided that includes at least one modifying moiety attached thereto. Modified natriuretic compound complex stimulates cGMP production, retains activity to bind to NPR-A receptor, and in some embodiments, improved half-life in circulation compared to unmodified counterpart natriuretic compound To do. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates can be prepared as therapeutics and / or therapies for cardiac conditions, particularly congestive heart failure. Also disclosed are modifying moieties comprising oligomeric structures having various lengths and configurations. Analogs of natriuretic compounds having amino acid sequences other than the native sequence are also disclosed. |